FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296250187> ?p ?o ?g. }

• W4296250187 endingPage "104270" @default.
• W4296250187 startingPage "104270" @default.
• W4296250187 abstract "Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. The introduction of global vaccine programs has contributed to lower COVID-19 hospitalisation and mortality rates, particularly in developed countries. In late 2021, Omicron BA.1 emerged, with substantially altered genetic differences and clinical effects from other variants of concern. Shortly after dominating global spread in early 2022, BA.1 was supplanted by the genetically distinct Omicron lineage BA.2. A sub-lineage of BA.2, designated BA.5, presently has an outgrowth advantage over BA.2 and other BA.2 sub-lineages. Here we study the neutralisation of Omicron BA.1, BA.2 and BA.5 and pre-Omicron variants using a range of vaccine and convalescent sera and therapeutic monoclonal antibodies using a live virus neutralisation assay. Using primary nasopharyngeal swabs, we also tested the relative fitness of BA.5 compared to pre-Omicron and Omicron viral lineages in their ability to use the ACE2-TMPRSS2 pathway.Using low passage clinical isolates of Clade A.2.2, Beta, Delta, BA.1, BA.2 and BA.5, we determined humoral neutralisation in vitro in vaccinated and convalescent cohorts, using concentrated human IgG pooled from thousands of plasma donors, and licensed monoclonal antibody therapies. We then determined infectivity to particle ratios in primary nasopharyngeal samples and expanded low passage isolates in a genetically engineered ACE2/TMPRSS2 cell line in the presence and absence of the TMPRSS2 inhibitor Nafamostat.Peak responses to 3 doses of BNT162b2 vaccine were associated with a 9-fold reduction in neutralisation for Omicron lineages BA.1, BA.2 and BA.5. Concentrated pooled human IgG from convalescent and vaccinated donors and BNT162b2 vaccination with BA.1 breakthrough infections were associated with greater breadth of neutralisation, although the potency was still reduced 7-fold across all Omicron lineages. Testing of clinical grade antibodies revealed a 14.3-fold reduction using Evusheld and 16.8-fold reduction using Sotrovimab for the BA.5. Whilst the infectivity of BA.1 and BA.2 was attenuated in ACE2/TMPRSS2 entry, BA.5 was observed to be equivalent to that of an early 2020 circulating clade and had greater sensitivity to the TMPRSS2 inhibitor Nafamostat.Observations support all Omicron variants to significantly escape neutralising antibodies across a range of vaccination and/or convalescent responses. Potency of therapeutic monoclonal antibodies is also reduced and differs across Omicron lineages. The key difference of BA.5 from other Omicron sub-variants is the reversion in tropism back to using the well-known ACE2-TMPRSS2 pathway, utilised efficiently by pre-Omicron lineages. Monitoring if these changes influence transmission and/or disease severity will be key for ongoing tracking and management of Omicron waves globally.This work was primarily supported by Australian Medical Foundation research grants MRF2005760 (ST, GM & WDR), MRF2001684 (ADK and ST) and Medical Research Future Fund Antiviral Development Call grant (WDR), Medical Research Future Fund COVID-19 grant (MRFF2001684, ADK & SGT) and the New South Wales Health COVID-19 Research Grants Round 2 (SGT)." @default.
• W4296250187 created "2022-09-19" @default.
• W4296250187 creator A5000689999 @default.
• W4296250187 creator A5008582636 @default.
• W4296250187 creator A5015493481 @default.
• W4296250187 creator A5016359253 @default.
• W4296250187 creator A5018301710 @default.
• W4296250187 creator A5020288642 @default.
• W4296250187 creator A5021810137 @default.
• W4296250187 creator A5026307062 @default.
• W4296250187 creator A5030747760 @default.
• W4296250187 creator A5034792012 @default.
• W4296250187 creator A5040638317 @default.
• W4296250187 creator A5041528010 @default.
• W4296250187 creator A5043335832 @default.
• W4296250187 creator A5045530644 @default.
• W4296250187 creator A5052729773 @default.
• W4296250187 creator A5053031023 @default.
• W4296250187 creator A5054938965 @default.
• W4296250187 creator A5055720036 @default.
• W4296250187 creator A5064660780 @default.
• W4296250187 creator A5065785507 @default.
• W4296250187 creator A5068421356 @default.
• W4296250187 creator A5069028488 @default.
• W4296250187 creator A5074086284 @default.
• W4296250187 creator A5078668563 @default.
• W4296250187 creator A5084064111 @default.
• W4296250187 creator A5086526042 @default.
• W4296250187 creator A5089216757 @default.
• W4296250187 creator A5089756299 @default.
• W4296250187 creator A5090954355 @default.
• W4296250187 date "2022-10-01" @default.
• W4296250187 modified "2023-10-16" @default.
• W4296250187 title "SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern" @default.
• W4296250187 cites W2048524411 @default.
• W4296250187 cites W2474614962 @default.
• W4296250187 cites W2997262256 @default.
• W4296250187 cites W3025744748 @default.
• W4296250187 cites W3112249938 @default.
• W4296250187 cites W3137970801 @default.
• W4296250187 cites W3171505118 @default.
• W4296250187 cites W3182196820 @default.
• W4296250187 cites W3198233589 @default.
• W4296250187 cites W3202714244 @default.
• W4296250187 cites W3210408195 @default.
• W4296250187 cites W4200216147 @default.
• W4296250187 cites W4200625712 @default.
• W4296250187 cites W4205140850 @default.
• W4296250187 cites W4206135665 @default.
• W4296250187 cites W4206153788 @default.
• W4296250187 cites W4206997616 @default.
• W4296250187 cites W4210308999 @default.
• W4296250187 cites W4210665241 @default.
• W4296250187 cites W4220874202 @default.
• W4296250187 cites W4220908383 @default.
• W4296250187 cites W4229333670 @default.
• W4296250187 cites W4281754639 @default.
• W4296250187 cites W4281815805 @default.
• W4296250187 cites W4283026725 @default.
• W4296250187 cites W4283319609 @default.
• W4296250187 cites W4283380375 @default.
• W4296250187 cites W4283687522 @default.
• W4296250187 cites W4283704819 @default.
• W4296250187 cites W4283831060 @default.
• W4296250187 cites W4286009139 @default.
• W4296250187 cites W4286220782 @default.
• W4296250187 cites W4286376092 @default.
• W4296250187 cites W4286696962 @default.
• W4296250187 doi "https://doi.org/10.1016/j.ebiom.2022.104270" @default.
• W4296250187 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36130476" @default.
• W4296250187 hasPublicationYear "2022" @default.
• W4296250187 type Work @default.
• W4296250187 citedByCount "78" @default.
• W4296250187 countsByYear W42962501872021 @default.
• W4296250187 countsByYear W42962501872022 @default.
• W4296250187 countsByYear W42962501872023 @default.
• W4296250187 crossrefType "journal-article" @default.
• W4296250187 hasAuthorship W4296250187A5000689999 @default.
• W4296250187 hasAuthorship W4296250187A5008582636 @default.
• W4296250187 hasAuthorship W4296250187A5015493481 @default.
• W4296250187 hasAuthorship W4296250187A5016359253 @default.
• W4296250187 hasAuthorship W4296250187A5018301710 @default.
• W4296250187 hasAuthorship W4296250187A5020288642 @default.
• W4296250187 hasAuthorship W4296250187A5021810137 @default.
• W4296250187 hasAuthorship W4296250187A5026307062 @default.
• W4296250187 hasAuthorship W4296250187A5030747760 @default.
• W4296250187 hasAuthorship W4296250187A5034792012 @default.
• W4296250187 hasAuthorship W4296250187A5040638317 @default.
• W4296250187 hasAuthorship W4296250187A5041528010 @default.
• W4296250187 hasAuthorship W4296250187A5043335832 @default.
• W4296250187 hasAuthorship W4296250187A5045530644 @default.
• W4296250187 hasAuthorship W4296250187A5052729773 @default.
• W4296250187 hasAuthorship W4296250187A5053031023 @default.
• W4296250187 hasAuthorship W4296250187A5054938965 @default.
• W4296250187 hasAuthorship W4296250187A5055720036 @default.
• W4296250187 hasAuthorship W4296250187A5064660780 @default.
• W4296250187 hasAuthorship W4296250187A5065785507 @default.
• W4296250187 hasAuthorship W4296250187A5068421356 @default.

• next